Analysis of the Efficacy of Immunotherapy in Elderly Patients with Lung Cancer
Conclusion The efficacy and safety of immunotherapy in elderly patients were similar to those in younger patients, and PFS was superior in the first-line immunotherapy. Further prospective studies are still needed to explore predictors of immunotherapy in elderly NSCLC patients.
DOI: 10.3779/j.issn.1009-3419.2022.102.16
Source: Chinese Journal of Lung Cancer - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | China Health | Clinical Trials | Immunotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Statistics | Study